HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for ...

LITTLE ROCK, Ark.--(BUSINESS WIRE)--Kuria Therapeutics, a pharmaceutical company developing novel ophthalmic and dermal therapeutics, announced that it has successfully closed its first fundraising ...

C4X Discovery Holdings plc has outlicensed its once daily oral NRF2 (Nuclear factor-erythroid factor 2-related factor 2) activator to Astrazeneca plc in a deal with a potential value of $402 million.

LITTLE ROCK, Ark.--(BUSINESS WIRE)--Kuria Therapeutics, a pharmaceutical company developing novel ophthalmic and dermal therapeutics, is pleased to announce it has completed a pre-Investigational New ...

AstraZeneca has moved to strengthen its respiratory disease pipeline, wagering $400 million in biobucks for the global rights to a preclinical C4X Discovery NRF2 activator program with applications in ...

BioWorld - Monday, December 30, 2024 Breaking News: Holiday special – 25% off BioWorld subscriptions See today's BioWorld Science Home » Fundraising at Kuria Therapeutics to advance topical ophthalmic ...

This is a preview. Log in through your library . Abstract The transcription factor Nrf2 is an important modulator of antioxidant and drug metabolism, carbohydrate and lipid metabolism, as well as heme ...

A team of researchers from Academia Sinica and National Taiwan University has identified the Drosophila Cul2 substrate ...